Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Q3 FY24 Earnings Presentation
9 slides from Aroa Biosurgery's earnings presentation, Jan 30, 2024
Slide 1: Aroa Biosurgery December Quarterly (Q3 FY24) Report
For personal use only AROA BIOSURGERY (ARX) DECEMBER QUARTERLY (Q3 FY24) REPORT Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 30 January has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a general backgrou
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM platform families for new products, line >US$3B1 TAM predominantly sold to US extensions & enables AROA’s hospitals for existing products tissue apposition platform US Direct
Slide 4: AROA ECM – Structure & Biology for Regenerative Healing
|4 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenes
Slide 5: Q3 Financial highlights
|5 Q3 Financial highlights NZ$17.7 million cash receipts from customers (20% increase in quarter-on-quarter) For personal use only Progress towards breakeven operational cashflows, with net cash outflows from operations decreasing to NZ$1.7 million from $3.2 million in the prior quarter. Net cash ou
Slide 6: Q3 Updated guidance
|6 Q3 Updated guidance Guidance reduced to NZ$67-70 million total revenue, NZ$66-69 million product revenue, 85% product gross margin and a normalised EBITDA loss of NZ$1-3 million. For personal use only One-off (H2 FY24) decrease in expected revenue from TELA Bio, Inc. (‘TELA Bio’) due to a previou
Slide 7: Q3 Operational highlights
|7 Q3 Operational highlights US FDA (‘FDA’) 510(k) clearance received for a new product, a resorbable dental barrier developed and manufactured from the Company’s proprietary AROA ECM platform technology. The For personal use only Company is actively pursuing a new partnership to commercialise this
Slide 8: Q&A
? For personal use only Q&A Unlocking regenerative healing for everybody
Slide 9: Contact
CONTACT For personal use only James Agnew m +64 21 744 915 investor@aroa.com Visit our website www.aroa.com and find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2150, Auckland 2022, New Zealand New Zealand Unl